Tdap vaccine

Phase 3Vaccine

Sanofi

Tdap vaccine is one of 14 biologic programs targeting Pregnant Women. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pregnant WomenNot yet recruiting

DiphtheriaNot yet recruiting

Pregnant WomenPhase 3

Not yet recruiting

DiphtheriaPhase 1

Not yet recruiting

Competition

Competitive Landscape

11 competitors in Pregnant Women

#DrugCompanyPhaseTrials

Vemlidy

Gilead

Approved

1 2

Tirosint

IInstitut Jerome Lejeune

Approved

1 3

GBS-NN/NN2

MMinervax ApS

Phase 3

2 4

Tdap vaccine

Sanofi

Phase 3

1 5

Hecolin ).

IInternational Vaccine Institute

Phase 2

1 6

Nicotinamide

MMetro International Biotech, LLC

Preclinical

1 7

IV Acetaminophen

AAFT Pharmaceuticals, Ltd.

Preclinical

1 8

Choline Bitartrate

UUniversity of Minnesota

Preclinical

1 9

Antiemetic Drug

UUniversity of West Attica

Preclinical

1 10

Shanchol

EEuBiologics Co.,Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Diphtheria

NCT07492303

ApprovedRecruiting

COVID-19 Vaccine

NCT07730450

Clinical

Trials by Indication[1]

Antibody Response1 trial

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women

Completed·MMahidol University·Phase 1·NCT03498300·129 enrolled

Diphtheria1 trial

A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)

Not yet recruiting·CChangchun BCHT Biotechnology Co.·Phase 1·NCT07492303·96 enrolled

Atopic Dermatitis1 trial

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Completed· LEO Pharma logo

LEO Pharma·Phase 2·NCT03562377·215 enrolled

Immune Response1 trial

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents

Completed· Novartis logo

Novartis·Phase 3·NCT00518180·1,620 enrolled

Pregnant Women1 trial

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Not yet recruiting·MMinervax ApS·Phase 2/3·NCT06494475·564 enrolled

2 more indications

Dermatitis, Atopic1 trial

A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis

Completed· Sanofi logo

Sanofi·Phase 2·NCT06015308·224 enrolled

COVID-19 Vaccine1 trial

A PHASE 4, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF A BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE AGAINST SARS-COV-2 AND EVALUATE THE CIRCULATING SARS-COV-2 SPIKE PROTEIN LEVEL IN HEALTHY PARTICIPANTS 18 THROUGH 64 YEARS OF AGE

Recruiting· BioNTech logo

BioNTech·Approved·NCT07730450·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tdap vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tdap vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tdap vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Tdap vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Antibody Response1 trial

Diphtheria1 trial

Atopic Dermatitis1 trial

Immune Response1 trial

Pregnant Women1 trial

Dermatitis, Atopic1 trial

COVID-19 Vaccine1 trial

References

Drug Info

Quick Facts

Related News